| scholarly article | Q13442814 |
| P2093 | author name string | Jesper Heldrup | |
| Laura B Ramsey | |||
| William Shuman | |||
| Alexander A Vinks | |||
| Tomoyuki Mizuno | |||
| Nieko C Punt | |||
| Zachary L Taylor | |||
| Adriana Navarro Sainz | |||
| Balaji Baskaran | |||
| Nicholas Felicelli | |||
| P2860 | cites work | Glucarpidase to combat toxic levels of methotrexate in patients | Q24605014 |
| Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure | Q28375743 | ||
| Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells | Q28476416 | ||
| Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia | Q31103489 | ||
| Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. | Q34131794 | ||
| Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients | Q34247793 | ||
| Polyglutamation of methotrexate. Is methotrexate a prodrug? | Q34552178 | ||
| Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer | Q34780653 | ||
| Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs | Q35060593 | ||
| Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition | Q35634476 | ||
| Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy | Q36478646 | ||
| Genome-wide study of methotrexate clearance replicates SLCO1B1. | Q36595293 | ||
| Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments | Q37034349 | ||
| Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects | Q37474395 | ||
| Glucarpidase following high-dose methotrexate: update on development | Q37635158 | ||
| Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity | Q38543699 | ||
| High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy | Q40086721 | ||
| Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. | Q40118820 | ||
| The pharmacology and clinical use of methotrexate | Q40158601 | ||
| Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate | Q41846508 | ||
| Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity | Q42556608 | ||
| Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia | Q43221788 | ||
| Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. | Q44108202 | ||
| Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy | Q44281596 | ||
| High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL) | Q44423326 | ||
| Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia | Q44473547 | ||
| High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma | Q44893142 | ||
| Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance | Q46446111 | ||
| Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. | Q47165422 | ||
| Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. | Q50501063 | ||
| Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. | Q50752200 | ||
| Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia. | Q51012681 | ||
| Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. | Q51763283 | ||
| Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. | Q51928567 | ||
| Glucarpidase Intervention for Delayed Methotrexate Clearance | Q87702034 | ||
| Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients | Q90498370 | ||
| Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates | Q90746848 | ||
| Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib | Q91197807 | ||
| NONMEM Tutorial Part I: Description of Commands and Options, with Simple Examples of Population Analysis | Q91773221 | ||
| The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group | Q91960784 | ||
| Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology | Q92473070 | ||
| P921 | main subject | pharmacokinetics | Q323936 |
| decision support system | Q330268 | ||
| methotrexate | Q422232 | ||
| P577 | publication date | 2020-06-19 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase |
Search more.